Linagliptin Modulation of Inflammation in Chronic Coronary Artery Disease
Linagliptin treatment was associated with a reduction of proinflammatory cytokines in the setting of chronically ischemic myocardium, with identified modulation of the NFκB pathway. Following treatment, there was found to be an increase in CD11c expression, demonstrating an increase in dendritic cells as a possible immune modulating cell population within the ischemic myocardium.
Authors
- Frank W. Sellke (ORCID: https://orcid.org/0000-0002-8886-801X)
- Mark Broadwin (ORCID: https://orcid.org/0000-0002-0393-9983)
- Dwight D. Harris (ORCID: https://orcid.org/0000-0001-8289-2740)
- M. Ruhul Abid (ORCID: https://orcid.org/0000-0003-2981-2638)
- Christopher Stone (ORCID: https://orcid.org/0000-0002-9621-5334)
- Meghamsh Kanuparthy (ORCID: https://orcid.org/0009-0005-7581-0555)
- Jad Hamze (ORCID: https://orcid.org/0009-0000-2758-8746)
- K.W. Muir (ORCID: https://orcid.org/0009-0002-6178-0306)
Institutions
- Brown University (US)
- Rhode Island Hospital (US)
Publication Details
- Journal
- Journal of Surgical Research
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.jss.2025.03.036
- Citations
- 1
- Primary Topic
- Atherosclerosis and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Foundation for the National Institutes of Health
- National Institutes of Health